Overnight Market report, page-1456

Some news in the air

CEO is in town today.
https://www.finnewsnetwork.com.au/archives/finance_news_network394432.html
From the talk, you can see he is in Sydney in person.

And then the AIPAC003 is officially online.
https://www.clinicaltrials.gov/ct2/show/NCT05747794

I guess it would be the matter of time we hear the starting of that Ph2 component.
Note that this AIPAC003 is a total 849 patients ph2/3 trial. That is something Immutep is not handle by themselves. So there will be a partner or buy off the shelf event some time down the line.

And then Merck last night just announced officially the failure of Keynote-641 and Keynote-789, one aggressive prostate cancer and one NSCLC.
https://www.merck.com/news/merck-provides-update-on-phase-3-trials-keynote-641-and-keynote-789/
By far, Merck's superstar Keytruda is pretty much reaching the maximum capacity. These two are the last two trials that Keytruda combining with Chemo. So whatever Keytruda with/without Chemo can do, is all out there.

Keynote-789 failed? No worry, there is Keynote-798 (TACTI-002) just in your backyard.
I just don't know how much more data EFTI needs to feed in to trigger an event?